Evidence map›Paper›PMID 36194352›Full record

ArticleCardiovascular drugs and therapy2024

The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials.

S P Radhoe, E Boersma, M Bertrand, W Remme, R Ferrari, K Fox, S MacMahon, J Chalmers, M L Simoons, J J Brugts

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

S P RadhoeDepartment of Cardiology, Thorax Center, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015GD, the Netherlands. s.radhoe@erasmusmc.nl.ORCID 0000-0002-1070-6715
E BoersmaDepartment of Cardiology, Thorax Center, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015GD, the Netherlands.
M BertrandLille Heart Institute, Lille, France.
W RemmeSTICARES Cardiovascular Research Institute, Rhoon, the Netherlands.
R FerrariDepartment of Cardiology, University of Ferrara, Ferrara, Italy.
K FoxNHLI, Imperial College and Royal Brompton Hospital, London, UK.
S MacMahonThe George Institute for Global Health, The University of NSW, Sydney, NSW, Australia.
J ChalmersThe George Institute for Global Health, The University of NSW, Sydney, NSW, Australia.
M L SimoonsDepartment of Cardiology, Thorax Center, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015GD, the Netherlands.
J J BrugtsDepartment of Cardiology, Thorax Center, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015GD, the Netherlands.
Erasmus MC · NLThe George Institute for Global Health · AULille’s Cardiology Hospital · FRRoyal Brompton Hospital · GBUniversity of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo study the effects of a perindopril-based regimen on cardiovascular (CV) outcomes in patients with vascular disease in relation to background statin therapy.

methodsA pooled analysis of the randomized ADVANCE, EUROPA, and PROGRESS trials was performed to evaluate CV outcomes in 29,463 patients with vascular disease treated with perindopril-based regimens versus placebo. The primary endpoint was a composite of CV mortality, nonfatal myocardial infarction, and stroke. Multivariable Cox regression analyses were performed to assess the effects of a perindopril-based regimen versus placebo in relation to statin use.

resultsAt randomization, 39.5% of the overall combined study population used statins. After a mean follow-up of 4.0 years (SD 1.0), the cumulative event-free survival was highest in the statin/perindopril group and lowest in the no statin/placebo group (91.2% vs. 85.6%, respectively, log-rank p < 0.001). In statin users (adjusted hazard ratio [aHR] 0.87, 95% confidence interval [CI] 0.77-0.98) and non-statin users (aHR 0.80, 95% CI 0.74-0.87), a perindopril-based regimen was associated with a significantly lower risk of the primary endpoint when compared to placebo. The additional treatment effect appeared numerically greater in non-statin users, but the observed difference was statistically nonsignificant.

conclusionOur data suggest that the treatment benefits of a perindopril-based regimen in patients with vascular disease are independent of statin use.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsStrokeAngiotensin-Converting Enzyme InhibitorsHumansPerindoprilTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsPerindoprilACE inhibitorHypertensionPerindoprilPreventionStatinVascular disease

Identifiers

PMID36194352
PMCPMC10876738
OpenAlexW4301392204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.